logo.png
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis
10 févr. 2025 08h45 HE | Palisade Bio, Inc.
Data presented at the 2025 Crohn’s and Colitis Congress  PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure ...
Logo edited.jpg
Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01 
10 févr. 2025 06h00 HE | Greenwich LifeSciences, Inc.
STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
image.png
Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones
04 févr. 2025 09h25 HE | Jupiter Neurosciences, Inc.
Jupiter, Florida, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented...
resized logo.png
Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
30 janv. 2025 17h17 HE | Processa Pharmaceuticals, Inc.
HANOVER, Md, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
logo.png
Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress
29 janv. 2025 08h45 HE | Palisade Bio, Inc.
Carlsbad, CA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on...
LOgo.png
Serina Therapeutics Announces Sale of UniverXome Subsidiary
15 janv. 2025 16h05 HE | Serina Therapeutics, Inc.
- Transaction eliminates $11.2 million in debt, strengthening financial position - HUNTSVILLE, AL, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics Inc. (“Serina”) (NYSE American: SER), a...
logo.png
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03 janv. 2025 17h20 HE | Palisade Bio, Inc.
Carlsbad, CA, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Picture1
Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board
17 déc. 2024 08h30 HE | Palisade Bio, Inc.
Carlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) --  Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Logo.png
Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules
13 déc. 2024 16h05 HE | Palisade Bio, Inc.
Carlsbad, CA, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Logo.png
Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules
12 déc. 2024 12h05 HE | Palisade Bio, Inc.
Carlsbad, CA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...